Myriad Genetics Executive and Leadership Team

Benjamin Wheeler, the Chief Financial Officer at Myriad Genetics, manages the company's financial strategy and operations. Overseeing all fiscal activities, Wheeler ensures robust financial planning, accurate reporting, and effective capital allocation to support Myriad's growth initiatives. This role involves close collaboration with other executive leaders to align financial objectives with the company's mission of advancing molecular diagnostics. By driving financial discipline and exploring strategic investment opportunities, Benjamin Wheeler strengthens the company's market position. The Chief Financial Officer's expertise is critical in navigating the financial landscape of the healthcare and biotechnology sectors, ensuring long-term sustainability and shareholder value for Myriad Genetics.

Melissa Gonzales, the President, Women's Health, Myriad Genetics, directs the strategic growth and operational execution for the company's women's health division. Overseeing product development, market expansion, and commercial strategies within this critical area, Gonzales ensures Myriad's diagnostic solutions effectively serve women's health needs. This leadership role involves driving innovation in genetic testing for conditions impacting women, from hereditary cancer syndromes to reproductive health. By fostering strong relationships with healthcare providers and key opinion leaders, Melissa Gonzales advances the adoption of Myriad's specialized tests. The President, Women's Health, Myriad Genetics, plays a pivotal role in enhancing patient outcomes and solidifying the company's leadership in women's health diagnostics.

Mark Verratti, the President at Myriad Genetics, spearheads the company's overarching business strategy and operational oversight. Directing key initiatives across various divisions, Verratti ensures alignment with Myriad's mission to discover and deliver transformative molecular diagnostic tests. This executive function involves guiding market penetration, fostering strategic partnerships, and optimizing business performance to support the company's expansion in major disease areas. By driving operational efficiencies and championing innovation, Mark Verratti strengthens Myriad Genetics' competitive position. The President's leadership is instrumental in navigating the complex healthcare landscape and advancing the company's commitment to improving patient lives through precise diagnostics.

Kevin Haas, the Chief Technology Officer at Myriad Genetics, directs the company's technological infrastructure and innovation pipeline. Overseeing all aspects of research and development technology, Haas ensures the company's diagnostic platforms remain at the forefront of molecular science. This leadership involves architecting scalable solutions that support the expansion of Myriad's test portfolio across critical disease areas. By driving advancements in data analytics and bioinformatics, Kevin Haas enhances the precision and efficiency of diagnostic testing. The Chief Technology Officer's strategic vision guides the integration of emerging technologies, solidifying Myriad Genetics' position as a leader in molecular diagnostics and supporting the delivery of actionable insights to healthcare providers worldwide.

Shereen Solaiman, the Chief People Officer at Myriad Genetics, leads the human capital strategy and organizational development. Overseeing all aspects of talent management, employee engagement, and corporate culture, Solaiman cultivates an environment that supports innovation and scientific excellence. This position involves developing programs that attract, retain, and develop top talent within the molecular diagnostics field. By fostering a culture of collaboration and continuous learning, Shereen Solaiman ensures Myriad Genetics has the skilled workforce necessary to achieve its mission. The Chief People Officer's strategic initiatives are vital for aligning people operations with the company's ambitious goals in disease discovery and testing.